Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases

Journal of Clinical Investigation

Volumn 115, Issue 12, 2005, Pages 3440-3450

  Li, Ning ^a   Zhao, Minglang ^a   Hilario Vargas, Julio ^a   Prisayanh, Phillip ^a   Warren, Simon ^a   Diaz, Luis A ^a   Roopenian, Derry C ^b   Liu, Zhi ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b JACKSON LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; HUMAN IMMUNOGLOBULIN; HUMAN IMMUNOGLOBULIN G; IMMUNOGLOBULIN G; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DESMOSOME; DRUG EFFICACY; DRUG MEGADOSE; MOUSE; NEWBORN; NONHUMAN; PATHOGENESIS; PEMPHIGOID; PEMPHIGUS; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; PHENOTYPE; PRIORITY JOURNAL; RECEPTOR BINDING;

ANIMALS; ANIMALS, NEWBORN; ANTIBODIES; AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNE DISEASES; DESMOGLEIN 1; DESMOGLEIN 3; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOTHERAPY; MICE; MICE, INBRED C57BL; NEUTROPHILS; PEMPHIGOID, BULLOUS; PEMPHIGUS; PHENOTYPE; RECEPTORS, FC;

EID: 31044440897     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI24394     Document Type: Article

References (74)

1. Stanley, J.R. 1999. Bullous pemphigoid. In Fitzpatrick's dermatology in general medicine. I.M. Freedberg, et al., editors. McGraw-Hill. New York, New York, USA. 666-671.
2. Stanley, J.R., Tanaka, T., Mueller, S., Klaus-Kovtun, V., and Roop, D. 1988. Isolation of complementary DNA for bullous pemphigoid antigen by use of patients' autoantibodies. J. Clin. Invest. 82:1864-1870.
3. Sawamura, D., Li, K., Chu, M.-L., and Uitto, J. 1991. Human bullous pemphigoid antigen (BPAG1). Amino acid sequences deduced from cloned cDNAs predict biologically important peptide segments and protein domains. J. Biol. Chem. 266:17784-17790.
4. Diaz, L.A., et al. 1990. Isolation of a human epidermal cDNA corresponding to the 180-kD autoantigen recognized by bullous pemphigoid and herpes gestationis sera. Immunolocalization of this protein to the hemidesmosome. J. Clin. Invest. 86:1088-1094.
5. Giudice, G.J., Emery, D.J., and Diaz, L.A. 1992. Cloning and primary structural analysis of the bullous pemphigoid autoantigen, BP-180. J. Invest. Dermatol. 99:243-250.
6. Giudice, G.J., et al. 1993. Bullous pemphigoid and herpes gestationis autoantibodies recognize a common non-collagenous site on the BP180 ectodomain. J. Immunol. 151:5742-5750.
7. Zillikens, D., et al. 1997. Tight clustering of extracellular BP180 epitopes recognized by bullous pemphigoid autoantibodies. J. Invest. Dermatol. 109:573-579.
8. Nousari, H.C., and Anhalt, G.J. 1999. Pemphigus and bullous pemphigoid. Lancet. 354:667-672.
9. Stanley, J.R. 1993. Cell adhesion molecules as targets of autoantibodies in pemphigus and pemphigoid, bullous disease due to defective epidermal cell adhesion. Adv. Immunol. 53:291-325.
10. Nguyen, V.T., Ndoye, A., and Grando, S.A. 2000. Pemphigus vulgaris antibody identifies pemphaxin. A novel keratinocyte annexin-like molecule binding acetylcholine. J. Biol. Chem. 275:29466-29476.
11. Nguyen, V.T., Ndoye, A., and Grando, S.A. 2000. Novel human α9 acetylcholine receptor regulating keratinocyte adhesion is targeted by pemphigus vulgaris autoimmunity. Am. J. Pathol. 157:1377-1391.
12. Kalish, R.S. 2000. Pemphigus vulgaris: the other half of the story. J. Clin. Invest. 106:1433-1435.
13. Anhalt, G.J., Labib, R.S., Voorhees, J.J., Beals, T.F., and Diaz, L.A. 1982. Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N. Engl. J. Med. 306:1189-1196.
14. Roscoe, J.T., et al. 1985. Brazilian pemphigus foliaceus autoantibodies are pathogenic to BALB/c mice by passive transfer. J. Invest. Dermatol. 85:538-541.
15. Amagai, M., Karpati, S., Prussick, R., Klaus-Kovtun, V., and Stanley, J.R. 1992. Autoantibodies against the amino-terminal cadherin binding domain of pemphigus vulgaris antigen are pathogenic. J. Clin. Invest. 90:919-926.
16. Amagai, M., Hashimoto, T., Green, K.J., Shimizu, N., and Nishikawa, T. 1995. Antigen-specific immunoadsorption of pathogenic autoantibodies in pemphigus foliaceus. J. Invest. Dermatol. 104:895-901.
17. Liu, Z., et al. 1993. A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J. Clin. Invest. 92:2480-2488.
18. Liu, Z., et al. 1995. The role of complement in experimental bullous pemphigoid. J. Clin. Invest. 95:1539-1544.
19. Liu, Z., et al. 1997. A major role for neutrophils in experimental bullous pemphigoid. J. Clin. Invest. 100:1256-1263.
20. Chen, R., Zhou, X., Diaz, L.A., Werb, Z., and Liu, Z. 2001. Mast cells play a key role in neutrophil recruitment in experimental bullous pemphigoid. J. Clin. Invest. 108:1151-1158. doi:10.1172/JCI200111494.
21. Yancey, K.B., and Egan, C.A. 2000. Pemphigoid: clinical, histologic, immunologic, and therapeutic considerations. JAMA. 284:350-356.
22. Toth, G.G., and Jonkman, M.F. 2001. Therapy of pemphigus. Clin. Dermatol. 19:761-767.
23. Khumalo, N.P., Murrell, D.F., Wojnarowska, F., and Kirtschig, G. 2002. A systematic review of treatments for bullous pemphigoid. Arch. Dermatol. 138:385-389.
24. Dutz, J.P., and Ho, V.C. 1998. Immunosuppressive agents in dermatology: an update. Dermatol. Clin. 16:235-251.
25. Kazatchkine, M.D., and Kaveri, S.V. 2001. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N. Engl. J. Med. 345:747-755.
26. Gelfand, E.W. 2001. Antibody-directed therapy: past, present and future. J. Allergy Clin. Immunol. 108:S111-S116.
27. van der Meche, F.G., and Schmitz, P.I. 1992. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group. N. Engl. J. Med. 326:1123-1129.
28. Gajdos, P., et al. 1984. High-dose intravenous gammaglobulin for myasthenia gravis. Lancet. 1:406-407.
29. Sultan, Y., Kazatchkine, M.D., Maisonneuve, P., and Nydegger, U.E. 1984. Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet. 2:765-768.
30. Dalakas, M.C., et al. 1993. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N. Engl. J. Med. 329:1993-2000.
31. Jayne, D.R., Davies, M.J., Fox, C.J., Black, C.M., and Lockwood, C.M. 1991. Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet. 337:1137-1139.
32. LeHoang, P., Cassoux, N., George, F., Kullmann, N., and Kazatchkine, M.D. 2000. Intravenous immunoglobulin (IVIg) for the treatment of birdshot retinochoroidopathy. Ocul. Immunol. Inflamm. 8:49-57.
33. Jolles, S. 2001. A review of high-dose intravenous immunoglobulin (hdIVIg) in the treatment of the autoimmune blistering disorders. Clin. Exp. Dermatol. 26:127-131.
34. Ahmed, A.R., and Dahl, M.V. 2003. Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Arch. Dermatol. 139:1051-1059.
35. Ballow, M. 1997. Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory diseases. J. Allergy Clin. Immunol. 100:151-157.
36. Debre, M., et al. 1993. Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet. 342:945-949.
37. Soubrane, C., et al. 1993. Biologic response to anti-CD16 monoclonal antibody therapy in a human immunodeficiency virus-related immune thrombocytopenic purpura patient. Blood. 81:15-19.
38. Clarkson, S.B., et al. 1986. Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody. N. Engl. J. Med. 314:1236-1239.
39. Mouthon, L., et al. 1996. Mechanisms of action of intravenous immune globulin in immune-mediated diseases. Clin. Exp. Immunol. 104:3-9.
40. Viard, I., et al. 1998. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 282:490-493.
41. Crow, A.R., Song, S., Semple, J.W., Freedman, J., and Lazarus, A.H. 2001. IVIg inhibits reticuloendothelial system function and ameliorates murine passiveimmune thrombocytopenia independent of antiidiotype reactivity. Br. J. Haematol. 115:679-686.
42. Masson, P.L. 1993. Elimination of infectious antigens and increase of IgG catabolism as possible modes of action of IVIg. J. Autoimmun. 6:683-689.
43. Yu, Z., and Lennon, V.A. 1999. Mechanism of intravenous immune globulin therapy in antibodymediated autoimmune diseases. N. Engl. J. Med. 340:227-228.
44. Bleeker, W.K., Teeling, J.L., and Hack, C.E. 2001. Accelerated autoantibody clearance by intravenous immunoglobulin therapy: studies in experimental models to determine the magnitude and time course of the effect. Blood. 98:3136-3142.
45. Pierangeli, S.S., Espinola, R., Liu, X., Harris, E.N., and Salmon, J.E. 2001. Identification of an Fcγ receptor-independent mechanism by which intravenous immunoglobulin ameliorates antiphospholipid antibody-induced thrombogenic phenotype. Arthritis Rheum. 44:876-883.
46. Hansen, R.J., and Balthasar, J.P. 2002. Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia. Blood. 100:2087-2093.
47. Hansen, R.J., and Balthasar, J.P. 2002. Intravenous immunoglobulin mediates an increase in antiplatelet antibody clearance via the FcRn receptor. Thromb. Haemost. 88:898-899.
48. Samuelsson, A., Towers, T.L., and Ravetch, J.V. 2001. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. 291:484-486.
49. Bruhns, P., Samuelsson, A., Pollard, J.W., and Ravetch, J.V. 2003. Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity. 18:573-581.
50. Akilesh, S., et al. 2004. The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease. J. Clin. Invest. 113:1328-1333. doi:10.1172/JCI200418838.
51. Takai, T., Ono, M., Hikida, M., Ohmori, H., and Ravetch, J.V. 1996. Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice. Nature. 379:346-349.
52. Clynes, R., et al. 1999. Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors. J. Exp. Med. 189:179-186.
53. van Lent, P., et al. 2003. The inhibitory receptor FcRII reduces joint inflammation and destruction in experimental immune complex-mediated arthritides not only by inhibition of FcRI/III but also by efficient clearance and endocytosis of immune complexes. Am. J. Pathol. 163:1839-1848.
54. Stefanescu, R.N., Olferiev, M., Liu, Y., and Pricop, L. 2004. Inhibitory Fc gamma receptors: from gene to disease. J. Clin. Immunol. 24:315-326.
55. Simister, N.E., and Mostov, K.E. 1989. An Fc receptor structurally related to MHC class I antigen. Nature. 337:184-187.
56. Story, C.M., Mikulska, J.E., and Simister, N.E. 1994. A major histocompatibility complex class Ilike Fc receptor cloned from human placenta: possible role in transfer of immunoglobulin G from mother to fetus. J. Exp. Med. 180:2377-2381.
57. Israel, E.J., et al. 1997. Expression of the neonatal Fc receptor, FcRn, on human intestinal epithelial cells. Immunology. 92:69-74.
58. Junghans, R.P., and Anderson, C.L. 1996. The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc. Natl. Acad. Sci. U. S. A. 93:5512-5516.
59. Roberts, D.M., Guenthert, M., and Rodewald, R. 1990. Isolation and characterization of the Fc receptor from the fetal yolk sac of the rat. J. Cell Biol. 111:1867-1876.
60. Zijlstra, M., et al. 1990. Beta 2-microglobulin deficient mice lack CD4-8+ cytolytic T cells. Nature. 344:742-746.
61. Medesan, C., Radu, C., Kim, J.K., Ghetie, V., and Ward, E.S. 1996. Localization of the site of the IgG molecule that regulates maternofetal transmission in mice. Eur. J. Immunol. 26:2533-2536.
62. Ghetie, V., et al. 1996. Abnormally short serum halflives of IgG in beta 2-microglobulin-deficient mice. Eur. J. Immunol. 26:690-696.
63. Israel, E.J., Wilsker, D.F., Hayes, K.C., Schoenfeld, D., and Simister, N.E. 1996. Increased clearance of IgG in mice that lack beta 2-microglobulin: possible protective role of FcRn. Immunology. 89:573-578.
64. Christianson, G.J., et al. 1997. Beta 2-microglobulin-deficient mice are protected from hypergammaglobulinemia and have defective antibody responses because of increased IgG catabolism. J. Immunol. 159:4781-4792.
65. Roopenian, D.C., et al. 2003. The MHC class-I like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. J. Immunol. 170:3528-3533.
66. Liu, Z., et al. 1997. β2 microglobulin-deficient mice are resistant to bullous pemphigoid. J. Exp. Med. 186:777-783.
67. Amagai, M., Nishikawa, T., Nousari, H.C., Anhalt, G.J., and Hashimoto, T. 1998. Antibodies against desmoglein 3 (pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic pemphigus and cause acantholysis in vivo in neonatal mice. J. Clin. Invest. 102:775-782.
68. Morrison, L.H., Labib, R.S., Zone, J.J., Diaz, L.A., and Anhalt, G.J. 1988. Herpes gestationis autoantibodies recognize a 180-kD human epidermal antigen. J. Clin. Invest. 81:2023-2026.
69. Bernard, P., et al. 1992. The major cicatricial pemphigoid antigen is a 180-kD protein that shows immunologic cross-reactivities with the bullous pemphigoid antigen. J. Invest. Dermatol. 99:174-179.
70. Tamada, Y., et al. 1999. Lichen planus pemphigoides: identification of 180 kD hemidesmosome antigen. J. Am. Acad. Dermatol. 32:883-887.
71. Siragam, V., et al. 2005. Can antibodies with specificity for soluble antigens mimic the therapeutic effects of IVIG in the treatment of autoimmune disease? J. Clin. Invest. 115:155-160. doi:10.1172/JCI200522753.
72. Li, N., Aoki, V., Hans-Filho, G., Rivitti, E.A., and Diaz, L.A. 2003. The role of intramolecular epitope spreading in the pathogenesis of endemic pemphigus foliaceus (fogo selvagem). J. Exp. Med. 197:1501-1510.
73. Liu, Z., et al. 1995. Molecular mapping of a pathogenically relevant BP180 epitope associated with experimentally induced murine bullous pemphigoid. J. Immunol. 155:5449-5454.
74. Warren, S.J., et al. 2003. The role of subclass switching in the pathogenesis of endemic pemphigus foliaceus. J. Invest. Dermatol. 120:104-108.